A premium portfolio of professional serums, ampoules and peels brought to 1,150+ clinics across the Emirates — on a commercial engine that scales from six reps to nine.
Year 1 is a deliberate build — a co-funded launch that turns demos into repeat orders. The team scales from six reps to nine in Year 3, and the model matures: deeper penetration, larger basket size, and operating leverage on a largely fixed cost base.
The portfolio powers a full protocol of physician-administered treatments — each consuming product per session and built around prescription-grade actives.
Intradermal microinjections of vitamins, minerals, amino acids and hyaluronic acid — delivering actives locally to stimulate cell regeneration and improve hydration, elasticity and radiance.
Controlled microneedles create microchannels that trigger tissue repair — activating collagen and elastin, remodeling the dermis and boosting absorption of actives to refine texture and firmness.
Controlled chemical exfoliation — superficial to deep — that drives epidermal and dermal renewal, evens tone, softens fine lines and scars, and stimulates collagen for smoother, rejuvenated skin.
Personalized supplementation of essential nutrients — vitamins, minerals, amino acids and antioxidants — dosed at optimal concentrations for each individual.
Creams, serums and gels with targeted actives — peptides, antioxidants and moisturizing agents — that complement professional procedures and maintain skin health between sessions.
Every formula is intended for healthcare professionals and prepared and dispensed only against a valid prescription, in line with current regulations.
Microneedling ampoules and hydrodermabrasion serums drive 60% of revenue. Every category is consumed per-treatment, creating a predictable monthly reorder cycle.
| Product | Format | Selling Price (AED) |
|---|
Selling prices are the venture's list prices to clinics. Products are supplied to the venture in-kind by LB Lab, so the venture carries no cost of goods — operating profit is simply revenue less operating expenses.
Demand clusters heavily in Dubai and Abu Dhabi, which together hold roughly three-quarters of the addressable aesthetic and dermatology base — shaping where the team is deployed first.
| Emirate | Regulator | Clinics | Physicians | Skin Specialists | Total Specialists | Distribution Priority |
|---|---|---|---|---|---|---|
| Total | — | 1,150 | 1,050 | 1,585 | 2,635 |
Two reps own Dubai's premium density; single reps cover Abu Dhabi, Sharjah/Ajman, the Northern Emirates and key accounts. From Year 3, three reps are added — a third Dubai patch, a second Abu Dhabi rep, and a dedicated aesthetic-groups lead — concentrating coverage where demand is densest.
| Rep / Territory | Focus Segment | Target Accts | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | 5-Yr Total |
|---|---|---|---|---|---|---|---|---|
| All Reps | — | 182 | 605,760 | 1,110,038 | 1,864,863 | 2,497,584 | 3,692,429 | 9,770,674 |
Each rep visits 20–25 clinics weekly and keeps 20–25 accounts active on a monthly cycle. Years 1–2 establish the market with six reps (~500 clinics/year); from Year 3 the team steps up to nine — reaching ~850–900 clinics and nearly doubling the active base. This scale-up is the lever behind the Year 3–5 revenue acceleration.
Year 1 is a co-funded build — sampling, demos and KOL visits seed the base, and the venture runs at a planned loss. Revenue turns operationally positive in Year 2, the team scales from six reps to nine in Year 3, and annual revenue compounds to AED 3.69M by Year 5 — a cumulative AED 9.77M across the plan.